HPRA approval & distribution agreement in Spain

Tissue Regenix Group PLC

30 October 2023

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')

HPRA approval & distribution agreement in Spain

HPRA approval to provide an Irish logistics hub for the distribution of allograft products in the EU

New exclusive distribution agreement for Tissue Regenix's allograft products in Spain

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that it has received approval from the Irish Health Products Regulatory Authority ('HPRA'), allowing the Company to set up a logistics hub in Ireland for the distribution of its allograft products within the European Union ('EU').

The HPRA regulates medicines and devices in Ireland for the benefit of people and animals, inspecting companies and facilities which test, make or distribute health products to ensure that they comply with relevant standards and legislation.

Tissue Regenix has also signed an exclusive distributor contract with Spineart España SLU ('Spineart') for the distribution of its allograft products in Spain. Spineart is a privately held medical device company that operates in over 60 markets, focused on simplifying surgery by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams and patients.

Daniel Lee, Chief Executive Officer of Tissue Regenix, commented: "Receiving HPRA approval is a great step for Tissue Regenix, as it will provide a logistics hub for the distribution of our allograft products to the European market. Following this, we are delighted to be partnering with Spineart to bring our allograft products to more customers in the EU. Spineart have a large global footprint that we hope in time can be leveraged to bring our products to more customers internationally."

For more information:

Tissue Regenix Group plc	www.tissueregenix.com
David Cocke, Chief Financial Officer	via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR)	Tel: [phone]
Alice Woodings	[e-mail]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

END